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ABSTRACT
Objective: Ticagrelor, cyclopentyl triazolopyrimidine drug, and Clopidogrel, second-generation thienopyridine drug are antiplatelet drugs indicated 
for the prevention of thrombotic events in patients with acute or chronic coronary syndromes. The aim of this study is to assess efficacy and safety 
outcomes of ticagrelor treatment versus Clopidogrel treatment in patients with stable coronary artery disease (stable angina) using maximal platelet 
aggregation percent (MPAP) method and platelet reactivity index percent (PRIP) method.
Methods: A total of 42 patients (27 male and 15 female), their ages ranging (48±8) years with stable angina enrolled from Ibn Albitar Center 
for Cardiac Surgery for this crossover study. After satisfying, the properties of inclusion criteria they screened for clopidogrel treatment 75 mg 
daily for 2 weeks than after 2 weeks periods of wash off they treated with ticagrelor 90 mg twice daily for another 2 weeks. Platelet reactivity 
was tested at baseline (before treatment), after 2 weeks treatment with clopidogrel and after another 2 weeks treatment with ticagrelor. 
Platelet reactivity measured by light transmittance aggregometry test and by vasodilator-stimulated phosphoprotein (VASP) phosphorylation 
test.
Results: The results of MPAP after 2 weeks treatment with clopidogrel or ticagrelor showed high significant reduction in platelet aggregation in 
patients with ticagrelor treatment as compared to clopidogrel treatment (30±6% vs. 44±8%). As well, the results of PRIP using VASP-phosphorylation 
after 2 weeks treatment with clopidogrel or ticagrelor showed high significant reduction in platelet aggregation in patients with ticagrelor treatment 
as compared to clopidogrel treatment (22±5% vs. 36±7%).
Conclusion: Treatment with ticagrelor produced a reduction in platelet reactivity consistent with the reduction in major adverse cardiovascular 
events and improved survival without increasing major bleeding.
Keywords: Clopidogrel, Ticagrelor, Major adverse cardiovascular events, Vasodilator-stimulated phosphoprotein.
INTRODUCTION
Clopidogrel is a prodrug that required biotransformation into its active 
metabolite that irreversibly bound to platelet P2Y12 receptor for the 
platelet’s lifespan (7–10) days and inhibits platelets activation and 
aggregation [1,2]. Inhibition of platelets aggregation using thienopyridine 
drug in addition to aspirin therapy amended the consequences of 
patients with acute coronary syndromes and patients with stents 
insertion as compared to patients with aspirin monotherapy [3].
Some patients after doing percutaneous coronary intervention and 
using clopidogrel drug with aspirin therapy may have high platelet 
reactivity (HPR) or may not response to clopidogrel; those patients may 
expose to higher rates of ischemic complication events [4].
Ticagrelor, a cyclopentyl triazolopyrimidine compound, is a 
nonthienopyridine drug and unlike thienopyridine drug, is reversibly 
bound to platelet P2Y12 receptor. Its inhibit platelet activation and 
aggregation with a rapid onset of action as compared to clopidogrel [5].
Many studies found that ticagrelor possess higher antiplatelet potency 
than clopidogrel, second-generation thienopyridine, and similar 
antiplatelet potency as prasugrel, third-generation thienopyridine. 
Therefore, ticagrelor can be used to reduce the risk of subsequent 
myocardial infarction and stent thrombosis [6,7].
As expected, due to the reversible binding of Ticagrelor with P2Y12 
receptor this may lead to disperse its antiplatelet effect more rapidly 
with less bleeding [8].
The purpose of this crossover study was to assay platelets aggregation 
using two methods; maximal platelet aggregation percent (MPAP) 
method and platelet reactivity index percent (PRIP) method with two 
different treatments ticagrelor treatment or clopidogrel treatment in 
the same patients with stable angina at different times.
METHODS
Of 60 patients (43 males and 17 females) their ages ranging (50–60) 
years with stable angina enrolled from Ibn Albitar Center for Cardiac 
Surgery, only 42 patients (27 males and 15 females), their ages ranging 
(48±8) years completed the designed period of this crossover study. 
The reasons for discontinuation-involved patients with normal levels 
of MPAP who are not need for using antiplatelet drugs, non-cooperative 
patients, and loss of follow-up.
The crossover study evaluated the same patients at different times in 
the presence and absence of the therapy under study with the presence 
of washout period for at least 2 weeks between two treatments.
The Institutional Ethics Committee in each study site approved patient 
selection and study protocol. Written informed consent was obtained 
from each patient.
Diagnoses made based on clinical symptoms, clinical biochemical 
tests (such as cardiac troponin I), and tests such as electrocardiogram, 
echocardiogram, and cardiac stress test. Exclusion criteria were 
involved patients with a history of acute coronary syndrome, bleeding, 
and concomitant therapy that has cytochrome P 3 A inhibitors or 
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inducers, concomitant antithrombotic treatment, hemoglobin (Hb) 
level <10 g/dl, liver disease, diabetes mellitus, renal failure, heart 
failure, and patients with neurological disorder such as epilepsy and 
tumors.
The patients treated with a maintenance dose of clopidogrel (Plavix, 
France) 75 mg daily for 2 weeks. Then, after a washout period of 
2 weeks, the patients treated with a maintenance dose of ticagrelor 
(Astrazeneca) 90 mg twice daily for another 2 weeks.
Blood samples were collected in vacutainer tubes containing 3.2% 
sodium citrate, after discarding first 3 ml of free-flowing blood, at 
baseline (day 0 of treatment), after 2 weeks treatment with clopidogrel 
and after 2 weeks treatment with ticagrelorin the morning after 2 h of 
the last dose of the drug intake to measure the MPAP and the PRIP.
The MPAP was assay by measuring the inhibition of ADP (20 μmol/L)-
induced platelet aggregation of platelet-rich plasma which expressed 
as change in light transmittance from baseline, with platelet-poor 
plasma used as a reference and quantitated by light transmission 
aggregometry [8].
Whereas the PRI was assay by using vasodilator-stimulated 
phosphoprotein (VASP) , platelet VASP-kit, which measured  platelet 
P2Y12 receptor reactivity, and quantified by flow cytometry [9].
Platelet reactivity was expressed as a PRI and calculated as:
PRIP =[MFI (PGE1) – MFI (PGE1 + ADP)/MFI (PGE1)] × 100.
Where MFI is mean fluorescence intensity, PGE1 is prostaglandin E1, 
and ADP is adenosine diphosphate. The (PRIP) ratio expressed as mean 
percentage of platelet reactivity and it is inversely correlated with 
antiplatelet drugs efficiency.
We used the following previously defined cut points of HPR associated 
with long-term ischemic event occurrence: >59% (20 μmol/L) ADP-
induced maximal platelet aggregation [6] and >50% PRI based on the 
VASP phosphorylation assay [9].
The primary safety endpoint was defined major bleeding as bleeding 
with clinically overt evidence or non, associated with a decrease in Hb≥ 
5 g/dl, and minor bleeding as bleeding associated with a decrease in Hb 
of <3 g/dl [7].
All numerical data stratified as mean±standard deviation with 95% 
confidence interval. Comparisons of continuous variables were 
assessed by Student’s t-test, p values of 0 <0.05 were regarded to be 
statistically significant. All statistical analyses were performed using 
Statistical Package for the Social Sciences version 18.0 for windows.
RESULTS
Baseline clinical data and demographic characteristics of the studied 
participants displayed in Table 1. The platelet responsiveness to ADP 
stimulation, MPAP, after 2 weeks treatment with clopidogrel 75 mg 
daily was highly appreciably lower as compared with its value at the 
baseline (before treatment).
Whereas the MPAP in the same patients after 2 weeks washout and after 
another 2 weeks treatment with ticagrelor 90 mg twice daily was highly 
appreciably, lower as compared with MPAP value at the baseline or after 
2 weeks treatment with clopidogrel 75 mg daily (Table 2 and Fig. 1).
As well, the high significant decrease was clarified in PRIP that 
measured by VASP-phosphorylation after 2 weeks treatment with 
clopidogrel 75 mg daily as compared with its value at the baseline 
(before treatment).
In addition, the PRIP in the same patients after 2 weeks washout 
and after another 2 weeks treatment with ticagrelor 90 mg twice 
daily was highly significantly decrease as compared with its value at 
the baseline or after 2 weeks treatment with clopidogrel 75 mg daily 
(Table 2 and Fig. 1).
As noted in Fig. 2, the bar graph revealed the variations of MPAP and 
PRIP versus baseline after 2 weeks treatments, high variation achieved 
Table 1: Baseline clinical data and demographic characteristics 
of the participants’ patients
Variables Patients
Number (n) 42
Gender (males, females) (27,15)
Age (years) 48±8
WBC count (1000/mm) 6.5±1.5
Platelet count (1000/mm) 220±55
S. Creatinine (μmol/L) 91.05±20.33
S. Uric acid (μ mol/L) 348±82.8
S.LDL-C (mmol/L) 2.978±0.388
S.HDL-C (mmol/L) 1.114±0.259
Data are presented as mean±SD (standard deviation) for continuous variables, 
μ mol/L: Micromole per liter, mmol/L: Millimole per liter, 1000/mm: Multiply 
by thousand cell per millimeter, Number (n): Sample size of the participants, 
S.LDL-C: Serum low-density lipoprotein cholesterol, S.HDL-C: Serum 
high-density lipoprotein cholesterol. SD: Standard deviation, WBC: White 
blood cell
Fig. 1: Line chart demonstrates the effect of Clopidogrel 75 mg 
daily treatment or ticagrelor 90 mg twice daily treatment on the 
mean maximal platelet aggregation percent or the mean platelet 
reactivity index percent at baseline (before treatment) and after 
2 weeks treatments, sample size (n)=42.
Fig. 2: Bar graph elucidated the percent variation of the mean 
maximal platelet aggregation percent and the mean platelet 
reactivity index percent versus baseline after 2 weeks treatment 
with clopidogrel or with ticagrelor, sample size (n)=42
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in patients on ticagrelor treatment 90 mg twice daily as compared to 
clopidogrel treatment 75 mg daily.
Analysis of adverse events showed that two minor bleeding occurred 
during ticagrelor treatment, and no bleeding occurred during 
clopidogrel treatment. As well, dyspnea episodes testified in five 
patients on ticagrelor therapy and three patients on clopidogrel 
therapy. On continuous treatment, dyspnea commonly ameliorated, 
especially when its intensity was mild to moderate.
Power analysis for the minimum detectable effect of clopidogrel 
treatment 75 mg daily or ticagrelor treatment 90 mg twice daily on 
MPAP and PRIP after 2 weeks of treatments are elucidated in Fig. 3.
There is 80% probability that a decrease of MPAP by 4.96% with 
clopidogrel treatment 75 mg daily can be described and by 4.33% 
with ticagrelor treatment 90 mg twice daily can also be described. As 
well, there is 80% probability that a decrease of PRIP by 4.74% with 
clopidogrel treatment 75 mg daily can be sensed and by 4.07% with 
ticagrelor treatment 90 mg twice daily can also be sensed.
DISCUSSION
The results of this study elucidated that treatment with the reversibly 
binding platelet P2Y12, ticagrelor, was greater inhibitor of platelet 
aggregation than clopidogrel and thereafter reduced major ischemic 
events by reducing cardiovascular death, myocardial infarction, and 
stroke without significantly increasing major bleeding, these results are 
consistent with the PLATO overall results [10,11].
Likewise, to the other study [12,13], the current study showed that 
ticagrelor treatment may associate with adverse events such as 
bradycardia and dyspnea, which may be related to the inhibitory effect 
of ticagrelor on adenosine reuptake by red blood cells.
Cannon et al. reported that the patients intended for non-invasive 
management and non-ST elevation coronary artery syndrome, 
exhibit higher rate of long-term adverse events than did those 
intended for invasive management [14]. As well, the patients who 
managed without revascularization usually have more comorbidity, 
higher risk of bleeding, and inferior outcome than patients who are 
revascularized [15].
Cannon et al. revealed that in contrast to clopidogrel treatment, 
ticagrelor treatment throughout the 1st week produced an additional 
ventricular gap that detected by Holter instrument [13]. Many studies 
reported a link between patients’ resistance to clopidogrel and major 
adverse cardiovascular events (MACE) [16-18].
VASP is a critical protein that is involved in the remodeling of the actin 
cytoskeleton, while in platelets it has a role in regulating adhesive 
events that are associated with platelet aggregation [19].
Flow cytometric assessment of VASP phosphorylation and the Verify 
Now P2Y12 assay has the advantage of measuring P2Y12 function directly, 
whereas ADP-induced platelet aggregation (light transmission) is 
influenced by P2Y12receptor and other receptor (P2Y1 receptor) which 
activate platelet and promoting platelet aggregation [20].
Some patients after taking antiplatelet drugs will have high post-
treatment platelet reactivity which is a better estimate of thrombotic 
risk than pre-treatment platelet reactivity [21]. Barragan et al. found 
that inhibition of platelet activity <50% using PRIP is preferred to reduce 
the risk of stent thrombosis [16]. Other study found that the mortality 
rate in patients with an acute coronary syndrome has not significantly 
reduced with clopidogrel treatment [2], or with glycoprotein IIb/IIIa 
inhibitors treatment [22].
Many studies reported various limitations of clopidogrel therapy which 
include variable and irreversible platelet inhibition, slow onset of 
action, modest level of platelet inhibition, and considerably proportion 
of patients exhibiting limited response [23]. However, numerous 
strategies have been used to improve responses to clopidogrel, 
including increasing dosages or adding other agents [24].
The values of international normalization ratio (INR) in some 
patients were falsely impaired and increased due to the interference 
of antiphospholipid antibody with thromboplastins [25]. In addition, 
some drugs can form a complex with platelets and trigger immune-
mediated thrombocytopenia that enhances platelets destruction and 
suppresses platelets levels [26].
CONCLUSION
Ticagrelor a reversibly platelet P2Y12 receptor binding oral drug has more 
intense platelets inhibition than Clopidogrel, and so reduces the risks of 
ischemic events and mortality without increasing major bleeding, and it 
may use to overcomes the non-responsiveness to clopidogrel.
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Fig. 3: Power analysis for the minimum detectable effect of 
clopidogrel treatment (75 mg daily) or ticagrelor treatment 
(90 mg twice daily) on maximal platelet aggregation percent and 
on platelet reactivity index percent after 2 weeks treatments. 
Assuming alpha=0.05, beta =0.2, power (1-beta)=0.8 (80 %), and 
sample size=42
Table 2: Comparison of differences in platelet aggregation response using MPAP method or PRIP method at baseline, after 2 weeks 
treatment with clopidogrel 75 mg daily and after another 2 weeks treatment with ticagrelor 90 mg twice daily
Variables Baseline (before treatment) Patients on clopidogrel 2 week Patients on ticagrelor 2 week
MPAP 85%±7.4 44%±8** 30%±6**†
PRIP 78%±6.5 36%±7** 22%±5**†
Data are presented as mean±SD (standard deviation) for continuous variables, sample size (n)=42 patients,** high significant decrease (p<0.001) as compared to 
baseline,†high significant decrease (p<0.001) as compared to MPAP or PRIP for patients on clopidogrel. PRIP: Platelet reactivity index percent, MRIP: Maximal platelet 
aggregation percent. SD: Standard deviation
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